During the last session, Aquestive Therapeutics Inc (NASDAQ:AQST)’s traded shares were 2.22 million, with the beta value of the company hitting 2.90. At the end of the trading day, the stock’s price was $4.10, reflecting an intraday loss of -1.44% or -$0.06. The 52-week high for the AQST share is $6.23, that puts it down -51.95 from that peak though still a striking 74.39% gain since the share price plummeted to a 52-week low of $1.05. The company’s market capitalization is $368.88M, and the average intraday trading volume over the past 10 days was 3.24 million shares, and the average trade volume was 2.24 million shares over the past three months.
Aquestive Therapeutics Inc (NASDAQ:AQST) trade information
Aquestive Therapeutics Inc (AQST) registered a -1.44% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.44% in intraday trading to $4.10, hitting a weekly high. The stock’s 5-day price performance is -3.76%, and it has moved by -18.49% in 30 days. Based on these gigs, the overall price performance for the year is 272.73%. The short interest in Aquestive Therapeutics Inc (NASDAQ:AQST) is 2.32 million shares and it means that shorts have 0.7 day(s) to cover.
Aquestive Therapeutics Inc (AQST) estimates and forecasts
Statistics show that Aquestive Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Aquestive Therapeutics Inc (AQST) shares have gone up 202.58% during the last six months, with a year-to-date growth rate less than the industry average at -176.92% against 9.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -172.70% this quarter and then jump 10.00% in the quarter after that. In the rating firms’ projections, revenue will increase 14.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $12.46 million as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to $12.53 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $11.13 million and $13.24 million respectively. In this case, analysts expect current quarter sales to grow by 11.90% and then drop by -5.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 46.61%. While earnings are projected to return -181.32% in 2024.
AQST Dividends
Aquestive Therapeutics Inc is due to release its next quarterly earnings between April 30 and May 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aquestive Therapeutics Inc (NASDAQ:AQST)’s Major holders
Aquestive Therapeutics Inc insiders own 5.03% of total outstanding shares while institutional holders control 27.93%, with the float percentage being 29.41%. Bratton Capital Management, LP is the largest shareholder of the company, while 64 institutions own stock in it. As of Jun 29, 2023, the company held over 9.81 million shares (or 14.70% of all shares), a total value of $16.19 million in shares.
The next largest institutional holding, with 1.56 million shares, is of Vanguard Group Inc’s that is approximately 2.34% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $2.57 million.
Also, the Mutual Funds coming in first place with the largest holdings of Aquestive Therapeutics Inc (AQST) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 0.93 million shares. This amounts to just over 1.40 percent of the company’s overall shares, with a $1.54 million market value. The same data shows that the other fund manager holds slightly less at 0.49 million, or about 0.74% of the stock, which is worth about $0.81 million.
